SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

CCCC

C4 Therapeutics, Inc.
MIXED
Impact 5/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Monitor upcoming data presentations at EHA (June 11-14) and ASCO (May 29-June 2) for cemsidomide; any positive results could act as catalysts. The revenue decline may cap upside, but the beat and pipeline progress support a neutral-to-positive near-term view.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.17
T+0 close · May 12, 2026 · via day close
Latest settled
+14.83%
T+60 · $3.64
Vs SPY
+10.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $3.17entry
  2. T+1 · 6mo ago +16.09%α +15.51% · $3.68
  3. T+5 · 6mo ago +1.58%α +1.50% · $3.22
  4. T+20 · 5mo ago +22.08%α +23.81% · $3.87
  5. T+60 · 3mo ago +14.83%α +10.44% · $3.64
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M consensus), but total revenue declined 15% YoY from $7.2M. The company highlighted clinical progress for cemsidomide and a new Roche collaboration, with a cash runway to end of 2028. The mixed earnings beat and pipeline catalysts are offset by the revenue decline.

Key Financial Metrics

EPS
−$0.18
est −$0.26 · +30.8%
Revenue
$6.2M
est $4.4M · +39.8% · -15.0% YoY
Rating
beat

Key Facts

  • Q1 2026 revenue $6.152 million, down from $7.238 million YoY
  • Net loss per share $-0.20, improved from $-0.37 YoY
  • Beat consensus EPS ($-0.26) and revenue ($4.4M)
  • Cash & equivalents $268.3 million; runway to end of 2028
  • Phase 2 MOMENTUM trial enrollment on track; Phase 1b combo trial with elranatamab dosed first patient
  • New Roche collaboration for degrader-antibody conjugates with $20M upfront

Financial Impact

Revenue declined 15% YoY to $6.2M; net loss narrowed to $25.1M; EPS beat consensus by 30.8%

revenuenet loss per sharecash position

Risk Factors

  • Clinical trial failure or delays for cemsidomide
  • Revenue decline trend may continue as collaboration agreements wind down
  • Dilution risk from cash burn and potential future capital raises

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292648

Track record

19 reports on CCCC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026